drugset / Trial / NCT03056118

Optimal Duration of Clopidogrel in Second-Generation Drug-Eluting Stents

NCT03056118 ↗

Phase 4 Completed 1368 enrolled Gangnam Severance Hospital
RandomizedFactorialSingle-blindTreatment

Summary

Investigators try to assess the safety of 6-months or 12-months maintenance of dual antiplatelet therapy (DAPT, aspirin + clopidogrel) in patients undergoing percutaneous coronary intervention using the Zotarolimus-eluting, Resolute Integrity™ stent (Medtronic Vascular Inc, Santa Rosa, CA) or the BioMatrix™ stent (Biosensors. Singapore).

Timeline

Start
2011-05-02
Primary completion
2015-06-01
Completion
2015-09-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule — —
Subject Clopidogrel Small molecule — —

Indications